Pfizer starts voluntary withdraw of OXBRYTA, benefit does not outweigh risks
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Medscape1h
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
biznews.com20h
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
The Pharma Letter21h
The week in pharma: action, reaction and insight – week to September 27
Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...